Quick Answer
RIGEL PHARMACEUTICALS INC reported Total Revenue of $294.28 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +64.1% in Total Revenue from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $3.58 million | Q3 2017: $900.0 thousand | Q2 2018: $1.79 million | Q3 2018: $4.87 million | Q4 2018: $37.86 million | Q1 2019: $12.62 million | Q2 2019: $10.41 million | Q3 2019: $20.86 million | Q4 2019: $15.40 million | Q1 2020: $55.76 million | Q2 2020: $16.02 million | Q3 2020: $18.39 million | Q4 2020: $18.45 million | Q1 2021: $81.02 million | Q2 2021: $26.27 million | Q3 2021: $21.54 million | Q1 2022: $16.74 million | Q2 2022: $29.82 million | Q3 2022: $22.41 million | Q1 2023: $26.07 million | Q2 2023: $26.89 million | Q3 2023: $28.13 million | Q1 2024: $29.53 million | Q2 2024: $36.84 million | Q3 2024: $55.31 million | Q1 2025: $53.33 million | Q2 2025: $101.69 million | Q3 2025: $69.46 million.
- Over the full 10 years of available data (2016 to 2025), RIGEL PHARMACEUTICALS INC's Total Revenue has grown by 1,343.8%.
- Historical annual values: Fiscal year 2025: $294.28 million | Fiscal year 2024: $179.28 million | Fiscal year 2023: $116.88 million | Fiscal year 2022: $120.24 million | Fiscal year 2021: $149.24 million | Fiscal year 2020: $108.62 million | Fiscal year 2019: $59.29 million | Fiscal year 2018: $44.51 million | Fiscal year 2017: $4.48 million | Fiscal year 2016: $20.38 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: